Top Markets
Coin of the day
Aerovate Therapeutics, Inc. Aerovate Therapeutics, Inc.

Aerovate Therapeutics, Inc.

AVTE
Rang in aandelen #5459
Aerovate Therapeutics, Inc. is a clinical-stage biopharmaceutical enterprise... Aerovate Therapeutics, Inc. is a clinical-stage biopharmaceutical enterprise focused on innovating therapies to enhance the well-being of patients afflicted with rare cardiopulmonary illnesses across the United States. The company's principal effort involves advancing AV-101, an inhaled dry powder variant of imatinib, which is currently undergoing a Phase 2b/Phase 3 clinical study for the management of pulmonary arterial hypertension. Established in 2018, Aerovate Therapeutics, Inc. maintains its corporate headquarters in Waltham, Massachusetts.
Aandeelprijs
$93.80
Laatst gesynchroniseerd: 2025-04-28
Marktkapitalisatie
$2.68B
Verandering (1 dag)
0.00%
Verandering (1 jaar)
0.00%
Land
US
Handel Aerovate Therapeutics, Inc. (AVTE)

Categorie

Dividendrendementgeschiedenis voor Aerovate Therapeutics, Inc. (AVTE)
Het dividendrendement (TTM) van Aerovate Therapeutics, Inc. (aandelsymbool: AVTE) per 2023-12-31 is: 0.00%
Gemiddeld dividendrendement over de afgelopen 5 jaar: 0.00%
Dividendrendementgeschiedenis van Aerovate Therapeutics, Inc. (AVTE) van 2020 tot 2026
Dividendrendement aan het einde van elk jaar (TTM)
Jaar Dividendrendement Wijzigen
2026 (TTM) 0.00% 0.00%
2024 0.00% 0.00%
2023 0.00% 0.00%
2022 0.00% 0.00%
2021 0.00% 0.00%
2020 0.00% 0.00%
Dividendrendementen (TTM) van vergelijkbare bedrijven of concurrenten
Bedrijf Dividendrendement Land
0.00%
US
0.00%
NL
0.00%
US
3.12%
AU
0.00%
CH